Understand the source comparison
Comparison: KPV vs Thymosin Alpha-1 vs BPC-157 for Eczema
Here's how the three best peptides for eczema differ in mechanism, administration, and clinical evidence: KPV Inhibits NF-κB transcription factor via IKK-β blockade Topical (1–5mg/mL) or subcutaneous Phase 2 human trials (open-label) 2–5mg topically BID or 500
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Here's how the three best peptides for eczema differ in mechanism, administration, and clinical evidence:
- KPV
- Inhibits NF-κB transcription factor via IKK-β blockade
- Topical (1–5mg/mL) or subcutaneous
- Phase 2 human trials (open-label)
- 2–5mg topically BID or 500mcg subcutaneous daily
- Best evidence for direct anti-inflammatory effect; topical route avoids systemic exposure
- Thymosin Alpha-1
- Enhances T-regulatory cell function; modulates dendritic cell maturation
- Subcutaneous injection only
- Randomized controlled trial (n=60)
- 1.6mg subcutaneous twice weekly
- Strongest evidence for immune retraining; effect persists post-treatment
- BPC-157
- Promotes VEGFR2 upregulation and fibroblast migration for barrier repair
- Subcutaneous injection (oral bioavailability poor)
- Animal models and case reports
- 200–400mcg subcutaneous daily
- Best for chronic lichenified eczema with barrier compromise; limited human trial data
- Combination Protocol
- Synergistic: KPV for acute inflammation + Tα1 for immune modulation + BPC-157 for repair
- Mixed (topical + subcutaneous)
- No published combination trials
- Sequential or concurrent based on flare phase
- Theoretical rationale strong; no safety data for combined use